Generic Name: cabotegravir + rilpivirine
Drug Class: Single-Tablet Regimens
Company: ViiV Healthcare and Janssen Therapeutics
Approval Status: Experimental
Generic Version Available: No
Cabenuva (cabotegravir + rilpivirine), a long-acting injectable regimen, is being studied as a treatment for HIV. It has not yet been reviewed for inclusion in the DHHS list of recommended HIV treatments.
Cabenuva (cabotegravir + rilpivirine) is an experimental HIV medication. It contains two different types of HIV drugs: the experimental integrase inhibitor cabotegravir and an injectable version of rilpivirine (sold in pill form as Edurant). It is currently in Phase III clinical trials.
This is a long-acting injectable regimen administered every four weeks.
For More Info: https://www.cabenuvahcp.com/
Patient Assistance Program Info: https://www.viivconnect.com/patient-assistance-program/
Last Reviewed: October 11, 2019